Literature DB >> 29225151

Injectable in situ forming gel based on lyotropic liquid crystal for persistent postoperative analgesia.

Liling Mei1, Yecheng Xie1, Ying Huang1, Bei Wang1, Jintian Chen1, Guilan Quan1, Xin Pan2, Hu Liu3, Lili Wang3, Xianguo Liu4, Chuanbin Wu1.   

Abstract

Local anesthetics have been widely used for postoperative analgesia. However, multiple injections or local infiltration is required due to the short half-lives of local anesthetics after single injection, which results in poor compliance and increasing medical expense. In this study, an in situ forming gel (ISFG) based on lyotropic liquid crystal was developed to deliver bupivacaine hydrochloride (BUP) for long-acting postoperative analgesia. BUP-ISFG was designed to be administrated as a precursor solution which would spontaneously transform into gel with well-defined internal nanostructures for sustained drug release at the site of administration when exposed to physiological fluid. A lamellar-hexagonal-cubic phase transition occurred during the in situ gelation. The lamellar phase of the precursor solution endows it with low viscosity for good syringeability while the unique nanostructures of hexagonal and cubic phases of the in situ gel provide sustained drug release. Persistent analgesia effect in vivo was achieved with BUP-ISFG, and the plasma BUP concentration was found to be steadier compared to commercially available BUP for injection. In addition, the ISFG displayed acceptable biocompatibility and good biodegradability. The findings are positive about ISFG as a sustained release system for persistent postoperative analgesia. STATEMENT OF SIGNIFICANCE: To address the issue of insufficient postoperative analgesia associated with short half-lives of local anesthetics after single injection, an in situ forming gel (ISFG) based on lyotropic liquid crystal was developed to deliver bupivacaine hydrochloride (BUP) for postoperative analgesia over three days. The results demonstrated that persistent analgesia effect in vivo was achieved with single injection of BUP-ISFG, and the plasma BUP concentration was found to be steadier compared to commercially available BUP injection. The BUP-ISFG possessed a lamellar-hexagonal-cubic phase transition with corresponding crystal change in 3D nanostructure during the in situ gelation. The relationship between crystal nanostructure and carrier function, might provide some insights to the design and clinical applications of the drug delivery systems based on lyotropic liquid crystal.
Copyright © 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  In situ forming gel; Local anesthetics; Lyotropic liquid crystal; Phase transition; Postoperative analgesia

Mesh:

Substances:

Year:  2017        PMID: 29225151     DOI: 10.1016/j.actbio.2017.11.057

Source DB:  PubMed          Journal:  Acta Biomater        ISSN: 1742-7061            Impact factor:   8.947


  4 in total

1.  In Situ Liquid Crystal Gel as a Promising Strategy for Improving Ocular Administration of Dexamethasone: Preparation, Characterization, and Evaluation.

Authors:  Wenqing Wu; Wenxuan Cao; Jingbao Chen; Ye Cai; Baoqi Dong; Xiaoqin Chu
Journal:  AAPS PharmSciTech       Date:  2021-12-23       Impact factor: 3.246

2.  Liquid crystal delivery of ciprofloxacin to treat infections of the female reproductive tract.

Authors:  Simone Pisano; Matteo Giustiniani; Lewis Francis; Deyarina Gonzalez; Lavinia Margarit; I Martin Sheldon; Donatella Paolino; Massimo Fresta; R Steven Conlan; Gareth D Healey
Journal:  Biomed Microdevices       Date:  2019-03-29       Impact factor: 2.838

3.  Study of the interaction between self-assembling peptide and mangiferin and in vitro release of mangiferin from in situ hydrogel.

Authors:  Cui Meng; Weipeng Wei; Yuhe Wang; Kunqin Zhang; Ting Zhang; Yunyan Tang; Fushan Tang
Journal:  Int J Nanomedicine       Date:  2019-09-12

4.  Smart phase transformation system based on lyotropic liquid crystalline@hard capsules for sustained release of hydrophilic and hydrophobic drugs.

Authors:  Xuejuan Zhang; Yujun Xiao; Zhengwei Huang; Jintian Chen; Yingtong Cui; Boyi Niu; Ying Huang; Xin Pan; Chuanbin Wu
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.